CN101563102A - 治疗内皮功能障碍的方法 - Google Patents
治疗内皮功能障碍的方法 Download PDFInfo
- Publication number
- CN101563102A CN101563102A CNA2007800398784A CN200780039878A CN101563102A CN 101563102 A CN101563102 A CN 101563102A CN A2007800398784 A CNA2007800398784 A CN A2007800398784A CN 200780039878 A CN200780039878 A CN 200780039878A CN 101563102 A CN101563102 A CN 101563102A
- Authority
- CN
- China
- Prior art keywords
- gly
- asp
- pro
- seq
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
Abstract
Description
处理 | 反应 | ||
TP508处理的细胞(正常氧) | ERK 1/2激活降低 | P70S6激活降低 | FAK激活增加 |
TP508预处理然后用TNFα处理的细胞 | 抑制TNFα诱导的ARG1增加 | 对ERK1/2磷酸化没有影响 | 对P70S6磷酸化没有影响 |
TP508处理,有或无TNFα处理 | eNOS表达增加 | eNOS激活增加 |
处理 | 反应 | |
细胞去血清,用VEGF和TP508处理 | 单独TP508处理不增加细胞存活率 | VEGF和TP508处理增加存活率,超过单独的VEGF |
TP508处理:正常氧 | eNOS表达上调 | VEGF、VEGFR1和VEGFR2表达:没有影响 |
TP508处理:低氧 | eNOS表达上调 | VEGF、VEGFR1和VEGFR2表达上调 |
Claims (81)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84641806P | 2006-09-22 | 2006-09-22 | |
US60/846,418 | 2006-09-22 | ||
US84800406P | 2006-09-28 | 2006-09-28 | |
US60/848,004 | 2006-09-28 | ||
US92264607P | 2007-04-10 | 2007-04-10 | |
US60/922,646 | 2007-04-10 | ||
PCT/US2007/020445 WO2008036387A2 (en) | 2006-09-22 | 2007-09-21 | Method of treating endothelial dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101563102A true CN101563102A (zh) | 2009-10-21 |
CN101563102B CN101563102B (zh) | 2014-12-17 |
Family
ID=39201107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780039878.4A Active CN101563102B (zh) | 2006-09-22 | 2007-09-21 | 治疗内皮功能障碍的方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8334259B2 (zh) |
EP (1) | EP2063910A2 (zh) |
JP (2) | JP2010504336A (zh) |
CN (1) | CN101563102B (zh) |
CA (1) | CA2663547C (zh) |
TW (1) | TWI486168B (zh) |
WO (1) | WO2008036387A2 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2155236A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for cardiac revascularization and cardiac repair |
CA2722621A1 (en) * | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Thrombin derived peptides for smooth muscle relaxation |
CA2722618A1 (en) | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating degenerative diseases |
CA2719940A1 (en) * | 2008-03-26 | 2009-11-26 | Orthologic Corp. | Methods for treating acute myocardial infarction |
EP2282754A2 (en) * | 2008-03-26 | 2011-02-16 | Orthologic Corp. | Method of treating peripheral arterial disease |
GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
AU2011265228A1 (en) * | 2010-06-11 | 2013-05-23 | The Board Of Regents, The University Of Texas System | Methods of mitigating effects of radiation and reducing the risk of systemic infection |
US10220078B2 (en) | 2014-06-11 | 2019-03-05 | The Board Of Regents Of The University Of Texas System | Methods of using thrombin derivatives to treat medulloblastoma |
US10881686B2 (en) | 2017-10-27 | 2021-01-05 | Zeta Biolongevity, Inc | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
US10905738B2 (en) * | 2018-07-05 | 2021-02-02 | Biozeus Desenvolvimento De Produtos Biofarmacêuticos | Synthetic peptides, prodrugs, pharmaceutical compositions and uses |
CN113092756A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液凝血酶原及其多肽片段在过敏性疾病中的应用 |
CA3179798A1 (en) * | 2020-04-07 | 2021-10-14 | Chrysalis Biotherapeutics | Tp508 acute therapy for patients with respiratory virus infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061689A1 (en) * | 2002-01-16 | 2003-07-31 | The Board Of Regents, The University Of Texas System | Thrombin derived peptides for promoting cardiac tissue repair |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352664A (en) | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
US5244460A (en) | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
US6086866A (en) | 1993-04-29 | 2000-07-11 | Kouri; Roger Khalil | Use of platelet-derived growth factor to improve collateral circulation |
CA2232240C (en) | 1995-10-24 | 2007-01-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Peptide for inhibiting growth of smooth muscle cells |
US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
US6197751B1 (en) | 1997-11-10 | 2001-03-06 | The United States Of America As Represented By The Department Of Health And Human Services | Thymosin α1 promotes tissue repair, angiogenesis and cell migration |
US6033436A (en) | 1998-02-17 | 2000-03-07 | Md3, Inc. | Expandable stent |
IL139030A0 (en) | 1998-04-17 | 2001-11-25 | Angiogenix Inc | Therapeutic angiogenic factors and methods for their use |
CN1338943A (zh) | 1998-10-26 | 2002-03-06 | 路德维格癌症研究院 | 利用vegf-c或vegf-d基因或蛋白预防再狭窄 |
US6363938B2 (en) | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
TWI257307B (en) | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
CN1458974A (zh) * | 2000-07-20 | 2003-11-26 | 德克萨斯系统大学董事会 | 用非蛋白质水解激活的凝血酶受体的激动剂刺激软骨生长 |
EP1539800B1 (en) * | 2002-07-02 | 2007-05-23 | Orthologic Corp. | Thrombin peptide derivative dimers |
EP1539214A4 (en) | 2002-07-02 | 2008-01-02 | Orthologic Corp | Thrombin |
DE602004005564T2 (de) * | 2003-12-31 | 2007-12-13 | Orthologic Corp., Tempe | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten |
-
2007
- 2007-09-21 WO PCT/US2007/020445 patent/WO2008036387A2/en active Application Filing
- 2007-09-21 CA CA2663547A patent/CA2663547C/en active Active
- 2007-09-21 CN CN200780039878.4A patent/CN101563102B/zh active Active
- 2007-09-21 TW TW096135320A patent/TWI486168B/zh not_active IP Right Cessation
- 2007-09-21 JP JP2009529248A patent/JP2010504336A/ja active Pending
- 2007-09-21 EP EP07861354A patent/EP2063910A2/en not_active Ceased
- 2007-09-21 US US12/311,130 patent/US8334259B2/en active Active
-
2012
- 2012-11-20 US US13/682,198 patent/US20130130978A1/en not_active Abandoned
-
2013
- 2013-04-22 JP JP2013089123A patent/JP2013166774A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061689A1 (en) * | 2002-01-16 | 2003-07-31 | The Board Of Regents, The University Of Texas System | Thrombin derived peptides for promoting cardiac tissue repair |
Non-Patent Citations (1)
Title |
---|
李建军: "血管内皮功能障碍及其检测与防治", 《中国动脉硬化杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CA2663547C (en) | 2020-08-25 |
WO2008036387A8 (en) | 2008-06-26 |
JP2010504336A (ja) | 2010-02-12 |
CN101563102B (zh) | 2014-12-17 |
US8334259B2 (en) | 2012-12-18 |
TW200829267A (en) | 2008-07-16 |
TWI486168B (zh) | 2015-06-01 |
EP2063910A2 (en) | 2009-06-03 |
US20090304671A1 (en) | 2009-12-10 |
CA2663547A1 (en) | 2008-03-27 |
WO2008036387A2 (en) | 2008-03-27 |
US20130130978A1 (en) | 2013-05-23 |
WO2008036387A3 (en) | 2008-12-04 |
JP2013166774A (ja) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101563102B (zh) | 治疗内皮功能障碍的方法 | |
KR100553629B1 (ko) | 혈전증치료에유용한항응고제 | |
AU7775900A (en) | Factor ix/factor ixa antibodies and antibody derivatives | |
KR20080113275A (ko) | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 | |
US20100303793A1 (en) | Combination therapy for cardiac revascularization and cardiac repair | |
US7935341B2 (en) | Antibodies to complementary peptides of thrombin or portions thereof | |
US20100330028A1 (en) | Combination therapy for chronic dermal ulcers | |
Boccardo et al. | Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis | |
US20060002969A1 (en) | Methods for reducing the foreign body reaction | |
Takei et al. | Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel | |
MXPA01006741A (es) | Metodos para reducir efectos secundarios adversos asociados con transplante celular. | |
US20060057140A1 (en) | Anticoagulant agents useful in treatment of thrombosis | |
KR20070116192A (ko) | 항혈전제 | |
WO2005041877A2 (en) | Method of inhibiting rejection following organ transplantation | |
JPH08507063A (ja) | Pdgfレセプタに対する抗体を使用した脈管内膜過形成の阻害 | |
US6436629B1 (en) | Modulating angiogenesis | |
EP2289542A1 (en) | Treatment of neurological or neurodegenerative disorders | |
CN111072780B (zh) | 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用 | |
GB2450747A (en) | Treatment of sensorineural hearing loss | |
US20160074483A1 (en) | Therapeutic peptide-expressing cells | |
Gospodarowicz et al. | The characterization of fibroblast growth factor and its biological effect in vitro and in vivo | |
Rotmans et al. | DIALYSIS-TRANSPLANTATION Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts. | |
UA100888C2 (uk) | Гуманізоване антитіло проти фактора d та його застосування |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST Free format text: FORMER OWNER: APEX TREATMENT INC. Effective date: 20130222 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Arizona, USA Applicant after: Vertex therapeutics Inc. Applicant after: Texas A&M University System Address before: Arizona, USA Applicant before: Osorogis Ltd. Applicant before: Texas A&M University System |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ORTHOLOGIC CORP. TO: APEX TREATMENT INC. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130222 Address after: Texas, USA Applicant after: BOARD OF REGENTS University OF TEXAS SYSTEM Applicant after: Texas A&M University System Address before: Arizona, USA Applicant before: Vertex therapeutics Inc. Applicant before: Texas A&M University System |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |